ORIGINAL: "The patient will receive trastuzumab daily"
IMPROVED: "The participant will receive trastuzumab daily with baseline ECHO/MUGA and cardiac monitoring per ACC guidance"
REASON: "HER2-targeted therapy requires cardiotoxicity monitoring and ICH-GCP terminology compliance"

---

ORIGINAL: Administer pembrolizumab every 3 weeks
IMPROVED: "Administer pembrolizumab every 3 weeks with immune-related adverse event monitoring including thyroid function, liver enzymes, and corticosteroid management protocol"
REASON: "Checkpoint inhibitor therapy requires systematic immune-related adverse event monitoring per FDA guidance"

---

ORIGINAL: "Collect ECG weekly"
IMPROVED: "Collect electrocardiogram (ECG) weekly using standardized 12-lead methodology"
REASON: "Protocol clarity requires standardized terminology and methodology specification"

---

ORIGINAL: Patient enrollment criteria
IMPROVED: Participant enrollment criteria  
REASON: Use 'participant' instead of 'patient' per ICH-GCP guidelines for clinical research

---

ORIGINAL: "Daily dosing will be administered"
IMPROVED: "Once daily dosing shall be administered"

---

ORIGINAL: "HER2-positive breast cancer patients receive therapy"
IMPROVED: "HER2-positive breast cancer participants receive therapy with baseline cardiac assessment and ongoing LVEF monitoring per cardio-oncology guidelines"
REASON: "HER2-targeted therapies require systematic cardiotoxicity monitoring due to established risk profile"

---

ORIGINAL: Monitor for side effects
IMPROVED: "Monitor for adverse events using CTCAE v5.0 grading criteria"
REASON: "Use standardized terminology 'adverse events' instead of 'side effects' per ICH-GCP requirements"

---

ORIGINAL: "Palbociclib 125mg will be given"  
IMPROVED: "Palbociclib 125mg shall be administered with complete blood count monitoring every 2 weeks for first 2 cycles, then monthly for neutropenia assessment"
REASON: "CDK4/6 inhibitors require systematic hematologic monitoring for dose-limiting neutropenia"

---

ORIGINAL: The doctor will assess eligibility
IMPROVED: "The investigator will assess participant eligibility"
REASON: Use 'investigator' and 'participant' terminology per clinical research standards

---

ORIGINAL: "Erlotinib therapy for EGFR mutations"
IMPROVED: "Erlotinib therapy for EGFR mutations with dermatologic toxicity monitoring and interstitial lung disease surveillance per prescribing information"
REASON: "EGFR inhibitors require monitoring for characteristic dermatologic and pulmonary toxicities"

---

ORIGINAL: Study drug administration  
IMPROVED: "Investigational product administration"

---

ORIGINAL: "Doxorubicin 60mg/m2 IV every 21 days"
IMPROVED: "Doxorubicin 60mg/m2 IV every 21 days with baseline and periodic ECHO/MUGA assessment for cumulative dose-dependent cardiotoxicity monitoring"
REASON: "Anthracyclines require systematic cardiac monitoring for dose-dependent cardiomyopathy risk per cardio-oncology consensus recommendations"